Product
PTM-001
1 clinical trial
1 indication
Indication
Hidradenitis SuppurativaClinical trial
A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial With a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis SuppurativaStatus: Recruiting, Estimated PCD: 2023-12-01